Vox Interview30 Jul 2019 19:54
I bought in last week having watched this share for a while and doubled up yesterday at the high - or at least the high for now.
I didn't think it was a bad interview at all, in fact I was genuinely glad to hear all of Justin Waite's concerns, as for me they did not add up to enough reasons to sell out or short the stock; far from it. He admitted to being jaded due to false dawns with TexRAD and the old CEO letting people down; said he'd been following FDBK and championing the stock for years but it had let him down, I think his words were 'and after a while you just stop believing it'. So that was his starting position, and his main reservation about buying now is price, he said people were urging him to buy in but said he won't do so on a spike - but perhaps he'll buy in tomorrow now it's come off a bit. AG's response was to point out that stock traded between 1.8 and 2p for a long time (and about 2 1/2p a year ago) and that was before Bleepa was born, so current price is not that high.
He mentioned competitors, but AG said barriers to entry for them are higher than for Bleepa, which can be rolled out quickly and is fully compliant and safe and secure. That NHS used faxes until recently is irrelevant; they already use WhatsApp, and Bleepa is a short step on that messaging curve.
He also underplayed revenue, mentioning it was ca £400k for the year, when it was in fact £563K, and that's obviously pre-Bleepa.
I therefore feel a bit uplifted having re-read the last two RNS' and listened twice to the VOX interview.
"We are making rapid progress in the development of our new messaging app, Bleepa. We believe that it will provide a flexible, accurate and secure method for swift clinical decision making, revolutionising the way in which patients receive treatment whilst safeguarding our doctors from potential litigation. We look forward to showcasing the finished product this September at NHS Expo in Manchester."
" The Directors believe this new product will also be the only communication tool to be a CE marked medical device… The repositioning of Cadran marks a shift away from a traditional software sales model towards a SaaS (software as a service) model which is anticipated to generate considerably higher recurring revenues for the Company and lead to a new phase of growth. With over 15 million doctors globally, Cadran is uniquely positioned to set new standards in this emerging, sizeable, medical communications market."
Good luck to all holders.